Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 7/2020

01-07-2020 | Glioblastoma | Review Article

Therapeutic potential of natural products in glioblastoma treatment: targeting key glioblastoma signaling pathways and epigenetic alterations

Authors: M. N. Abbas, S. Kausar, H. Cui

Published in: Clinical and Translational Oncology | Issue 7/2020

Login to get access

Abstract

Glioma is the most common primary tumor of the nervous system, and approximately 50% of patients exhibit the most aggressive form of the cancer, glioblastoma. Currently, considerable research in glioblastoma therapeutics is aimed at developing vaccines or drugs to target key molecules for combating this disease. Studies on plant natural products from spices, vegetables, fruits, teas, and traditional medicinal herbs display that these plant-derived natural products can act as effective antioxidant and anti-tumor agents. The advancements in metabolomics and in genomics have enabled researchers to better evaluate the potential use of immunomodulatory natural plant products for treatment of different cancerous diseases. The glioblastoma protective activities of the different natural plant products lie in their effects on cellular defenses such as antioxidant enzyme systems, detoxification and the stimulation of anti-inflammatory, anti-metastasis responses and by modifying epigenetic alterations, often through targeting specific key transcription factors such as activator protein, nuclear factor kappa B, signal transducers and activators of transcription and so on. Here, we review recent knowledge on the molecular mechanisms by which different inflammatory activities are linked to progression of glioblastoma and the particular immunomodulatory plant products that may reduce inflammation and the associated progression and metastasis of glioblastoma both in vitro and in vivo. Furthermore, their impact on the epigenetic alterations will also be discussed.
Literature
1.
Lin TY, Lee CC, Chen KC, Lin CJ, Shih CM. Inhibition of RNA transportation induces glioma cell apoptosis via downregulation of RanGAP1 expression. Chem Biol Interact. 2015;232:49–57.PubMedCrossRef
2.
Yuan Y, Xue X, Guo RB, Sun XL, Hu G. Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway. CNS Neurosci Ther. 2012;18:536–46.PubMedPubMedCentralCrossRef
3.
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401.PubMedCrossRef
4.
5.
Kim H, Moon JY, Ahn KS, Cho SK. Quercetin induces mitochondrial mediated apoptosis and protective autophagy in human glioblastoma U373MG cells. Oxid Med Cell Longev. 2013;2013:596496.PubMedPubMedCentral
6.
Salvesen GS, Duckett CS. IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol. 2002;3:401–10.PubMedCrossRef
7.
Khaw AK, Sameni S, Venkatesan S, Kalthur G, Hande MP. Plumbagin alters telomere dynamics, induces DNA damage and cell death in human brain tumour cells. Mutat Res Genet Toxicol Environ Mutagen. 2015;793:86–95.PubMedCrossRef
8.
Mishra R, Kaur G. Aqueous ethanolic extract of Tinospora cordifolia as a potential candidate for differentiation based therapy of glioblastomas. PLoS One. 2013;8:e78764.PubMedPubMedCentralCrossRef
9.
Guerram M, Jiang ZZ, Sun L, Zhu X, Zhang LY. Antineoplastic effects of deoxypodophyllotoxin, a potent cytotoxic agent of plant origin, on glioblastoma U-87 MG and SF126 cells. Pharmacol Rep. 2015;67:245–52.PubMedCrossRef
10.
Hahm SW, Park J, Son YS. Opuntia humifusa partitioned extracts inhibit the growth of U87MG human glioblastoma cells. Plant Foods Hum Nutr. 2010;65:247–52.PubMedCrossRef
11.
Michaud-Levesque J, Bousquet-Gagnon N, Beliveau R. Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration. Exp Cell Res. 2012;318:925–35.PubMedCrossRef
12.
Racoma IO, Meisen WH, Wang QE, Kaur B, Wani AA. Thymoquinone inhibits autophagy and induces cathepsin mediated, caspase-independent cell death in glioblastoma cells. PLoS One. 2013;8:e72882.PubMedPubMedCentralCrossRef
13.
Abdullah Thani NA, Sallis B, Nuttall R, Schubert FR, Ahsan M, Davies D, Purewal S, Cooper A, Rooprai HK. Induction of apoptosis and reduction of MMP gene expression in the U373 cell line by polyphenolics in Aronia melanocarpa and by curcumin. Oncol Rep. 2012;28:1435–42.PubMedCrossRef
14.
Liu Q, Xu X, Zhao M, Wei Z, Li X, Zhang X, Liu Z, Gong Y, Shao C. Berberine induces senescence of human glioblastoma cells by downregulating the EGFR-MEK-ERK signaling pathway. Mol Cancer Ther. 2015;14:355–63.PubMedCrossRef
15.
Suresh D, Srinivasan K. Tissue distribution & elimination of capsaicin, piperine & curcumin following oral intake in rats. Indian J Med Res. 2010;131:682–91.PubMed
16.
Ramachandran C, Portalatin G, Quirin KW, Escalon E, Khatib Z, Melnick SJ. Inhibition of AKT signaling by supercritical CO2 extract of mango ginger (Curcuma amada Roxb.) in human glioblastoma cells. J Complement Integr Med. 2015;12:307–15.PubMedCrossRef
17.
Kuete V, Sandjo LP, Ouete JL, Fouotsa H, Wiench B, Efferth T. Cytotoxicity and modes of action of three naturally occurring xanthones (8-hydroxycudraxanthone G, morusignin I and cudraxanthone I) against sensitive and multidrug-resistant cancer cell lines. Phytomedicine. 2014;21:315–22.PubMedCrossRef
18.
Li Y, Zhang P, Qiu F, Chen L, Miao C, Li J, Xiao W, Ma E. Inactivation of PI3K/Akt signaling mediates proliferation inhibition and G2/M phase arrest induced by andrographolide in human glioblastoma cells. Life Sci. 2012;90:962–7.PubMedCrossRef
19.
Bates S, Parry D, Bonetta L, Vousden K, Dickson C, et al. Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene. 1994;9:1633–40.PubMed
20.
Aravindaram K, Yang NS. Anti-inflammatory plant natural products for cancer therapy. Planta Med. 2010;76:1103–17.PubMedCrossRef
21.
Perry MC, Demeule M, Regina A, Moumdjian R, Beliveau R. Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts. Mol Nutr Food Res. 2010;54:1192–201.PubMed
22.
Miao J, Jiang Y, Wang D, Zhou J, Fan C, Jiao F, Liu B, Zhang J, Wang Y, Zhang Q. Trichosanthin suppresses the proliferation of glioma cells by inhibiting LGR5 expression and the Wnt/beta-catenin signaling pathway. Oncol Rep. 2015;34:2845–52.PubMedPubMedCentralCrossRef
23.
Bezivin C, Tomasi S, Lohezic-Le Devehat F, Boustie J. Cytotoxic activity of some lichen extracts on murine and human cancer cell lines. Phytomedicine. 2003;10:499–503.PubMedCrossRef
24.
Schmidt ML, Kuzmanoff KL, Ling-Indeck L, Pezzuto JM. Betulinic acid induces apoptosis in human neuroblastoma cell lines. Eur J Cancer. 1997;33:2007–10.PubMedCrossRef
25.
Liao MH, Lin WC, Wen HC, Pu HF. Tithonia diversifolia and its main active component tagitinin C induce survivin inhibition and G2/M arrest in human malignant glioblastoma cells. Fitoterapia. 2011;82:331–41.PubMedCrossRef
26.
Dissanayake AA, Bejcek BE, Zhang CR, Nair MG. Sesquiterpenoid lactones in Tanacetum huronense inhibit human glioblastoma cell proliferation. Nat Prod Commun. 2016;11:579–82.PubMed
27.
Ismail AM, Musa AM, Nasir T, Magaji MG, Jega YA, Ibrahim I. Anti-proliferative study and isolation of Ochna flavone from the ethyl acetate-soluble fraction of Ochna kibbiensis Hutch & Dalziel. Nat Prod Res. 2017;31:2149–52.PubMedCrossRef
28.
Fan Y, Xue W, Schachner M, Zhao W. Honokiol eliminates glioma/glioblastoma stem cell-like cells via JAK-STAT3 signaling and inhibits tumor progression by targeting epidermal growth factor receptor. Cancers. 2018;26:11.
29.
Borawska MH, Naliwajko SK, Moskwa J, Markiewicz-Żukowska R, Puścion-Jakubik A, Soroczyńska J. Anti-proliferative and anti-migration effects of polish propolis combined with Hypericum perforatum L. on glioblastoma multiform cell line U87MG. BMC Complement Altern Med. 2016;16:367.PubMedPubMedCentralCrossRef
30.
Schotterl S, Hubner M, Armento A, Veninga V, Wirsik NM, Bernatz S, Lentzen H, Mittelbronn M, Naumann U. Viscumins functionally modulate cell motility-associated gene expression. Int J Oncol. 2017;50:684–96.PubMedCrossRef
31.
32.
Khan M, Yu B, Rasul A, Al Shawi A, Yi F, Yang H, Ma T. Jaceosidin induces apoptosis in U87 glioblastoma cells through g2/m phase arrest. Evid Based Complement Alternat Med. 2012;2012:703034.PubMed
33.
Wang Y, Tang H, Zhang Y, Li J, Li B, Gao Z, Wang X, Cheng G, Fei Z. Saponin B, a novel cytostatic compound purified from Anemone taipaiensis, induces apoptosis in a human glioblastoma cell line. Int J Mol Med. 2013;32:1077–84.PubMedCrossRef
34.
Li J, Tang H, Zhang Y, Tang C, Li B, Wang Y, Gao Z, Luo P, Yin A, Wang X, Cheng G, Fei Z. Saponin 1 induces apoptosis and suppresses NF-kappaB-mediated survival signaling in glioblastoma multiform (GBM). PLoS One. 2013;8:e81258.PubMedPubMedCentralCrossRef
35.
Ji CC, Tang HF, Hu YY, Zhang Y, Zheng MH, Qin HY, Li SZ, Wang XY, Fei Z, Cheng G. Saponin 6 derived from Anemone taipaiensis induces U87 human malignant glioblastoma cell apoptosis via regulation of Fas and Bcl2 family proteins. Mol Med Rep. 2016;14:380–6.PubMedCrossRef
36.
37.
Rooprai HK, Christidou M, Pilkington GJ. The potential for strategies using micronutrients and heterocyclic drugs to treat invasive gliomas. Acta Neurochir (Wien). 2003;145:683–90.CrossRef
38.
Chang HF, Huang WT, Chen HJ, Yang LL. Apoptotic effects of gamma-mangostin from the fruit hull of Garcinia mangostana on human malignant glioma cells. Molecules. 2010;15:8953–66.PubMedPubMedCentralCrossRef
39.
Wick W, Grimmel C, Wagenknecht B, Dichgans J, Weller M. Betulinic acid-induced apoptosis in glioma cells: a sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J Pharmacol Exp Ther. 1999;289:1306–12.PubMed
40.
Kapoor H, Yadav N, Chopra M, Mahapatra SC, Agrawal V. Strong anti-tumorous potential of Nardostachys jatamansi rhizome extract on glioblastoma and in silico analysis of its molecular drug targets. Curr Cancer Drug Targets. 2017;17:74–88.PubMedCrossRef
41.
Eom KS, Kim HJ, So HS, Park R, Kim TY. Berberine induced apoptosis in human glioblastoma T98G cells is mediated by endoplasmic reticulum stress accompanying reactive oxygen species and mitochondrial dysfunction. Biol Pharm Bull. 2010;33:1644–9.PubMedCrossRef
42.
43.
Mounira K, Nouha N, Imen M, Kamel G, Leila CG. Limoniastrum guyonianum extracts induce apoptosis via DNA damage, PARP cleavage and UHRF1 down-regulation in human glioma U373 cells. J Nat Prod. 2014;7:79–86.
44.
45.
46.
Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029–39.PubMedPubMedCentral
47.
Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P. Tumor invasion and matrix metalloproteinases. Crit Rev Oncol Hematol. 2004;49:179–86.PubMedCrossRef
48.
Lin MT, Yen ML, Lin CY, Kuo ML. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol. 2003;64:1029–36.PubMedCrossRef
49.
Freitas S, Costa S, Azevedo C, Carvalho G, Freire S, Barbosa P, Velozo E, Schaer R, Tardy M, Meyer R, Nascimento I. Flavonoids inhibit angiogenic cytokine production by human glioma cells. Phytother Res. 2011;25:916–21.PubMedCrossRef
50.
Zhang FJ, Yang JY, Mou YH, Sun BS, Ping YF, Wang JM, Bian XW, Wu CF. Inhibition of U-87 human glioblastoma cell proliferation and formyl peptide receptor function by oligomer procyanidins (F2) isolated from grape seeds. Chem Biol Interact. 2009;179:419–29.PubMedCrossRef
51.
Zheng HL, Yang J, Hou Y, Sun B, Zhang Q, Mou Y, Wand L, Wu C. Oligomer procyanidins (F2) isolated from grape seeds inhibits tumor angiogenesis and cell invasion by targeting HIF-1alpha in vitro. Int J Oncol. 2015;46:708–20.PubMedCrossRef
52.
Huang H, Lin H, Zhang X, Li J. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-kappaB-dependent pathway. Oncol Rep. 2012;27:2050–6.PubMedCrossRef
53.
Cui Y, Bai Y, Wang XD, Liu B, Zhao Z, Wang LS. Differential expression of miRNA in rat myocardial tissues under psychological and physical stress. Exp Ther Med. 2014;7:901–6.PubMedPubMedCentralCrossRef
54.
Sun C, Yu Y, Wang L, Wu B, Xia L, Feng F, Ling Z, Wang S. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro. J Exp Clin Cancer Res. 2016;35:32.PubMedPubMedCentralCrossRef
55.
Elhag R, Mazzio EA, Soliman KF. The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines. Anticancer Res. 2015;35(3):1263–9.PubMedPubMedCentral
56.
Chakrabarti M, Ray SK. Synergistic anti-tumor actions of luteolin and silibinin prevented cell migration and invasion and induced apoptosis in glioblastoma SNB19 cells and glioblastoma stem cells. Brain Res. 2015;1629:85–93.PubMedCrossRef
57.
Chakrabarti M, Ray SK. Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. Apoptosis. 2016;21(3):312–28.PubMedCrossRef
58.
Bai ZL, Tay V, Guo SZ, Ren J, Shu MG. Silibinin induced human glioblastoma cell apoptosis concomitant with autophagy through simultaneous inhibition of mTOR and YAP. Biomed Res Int. 2018;2018:6165192.PubMedPubMedCentral
59.
Verdura S, Cuyàs E, Llorach-Parés L, Pérez-Sánchez A, Micol V, Nonell-Canals A, Joven J, Valiente M, Sánchez-Martínez M, Bosch-Barrera J, Menendez JA. Silibinin is a direct inhibitor of STAT3. Food Chem Toxicol. 2018;116(Pt B):161–72.PubMedCrossRef
60.
Chang N, Ahn SH, Kong DS, Lee HW, Nam DH. The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment. Mol Cell Endocrinol. 2017;451:53–65.PubMedCrossRef
61.
Pérez-Sánchez A, Cuyàs E, Ruiz-Torres V, Agulló-Chazarra L, Verdura S, González-Álvarez I, Bermejo M, Joven J, Micol V, Bosch-Barrera J, Menendez JA. intestinal permeability study of clinically relevant formulations of silibinin in Caco-2 cell monolayers. Int J Mol Sci. 2019;20(7):1606.PubMedCentralCrossRef
62.
Nico B, Ribatti D. Morpho-functional aspects of the blood brain barrier. Curr Drug Metab. 2012;13:50–60.PubMedCrossRef
63.
Schinkel AH. P-Glycoprotein, a gatekeeper in the bloodbrain barrier. Adv Drug Deliv Rev. 1999;36:179–94.PubMedCrossRef
64.
65.
Lecuyer MA, Kebir H, Prat A. Glial influences on BBB functions and molecular players in immune cell trafficking. Biochim Biophys Acta. 2016;1862:472–82.PubMedCrossRef
66.
Zhao X, Chen R, Liu M, Feng J, Chen J, Hu K. Remodeling the blood-brain barrier microenvironment by natural products for brain tumor therapy. Acta Pharm Sin B. 2017;7:541–53.PubMedPubMedCentralCrossRef
67.
van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1–12.PubMedCrossRef
68.
Jacobs VL, Landry RP, Liu Y, Romero-Sandoval EA, De Leo JA. Propentofylline decreases tumor growth in a rodent model of glioblastoma multiform by a direct mechanism on microglia. Neuro Oncol. 2012;14:119–31.PubMedCrossRef
69.
Staniforth V, Wang SY, Shyur LF, Yang NS. Shikonins, phytocompounds from Lithospermum erythrorhizon, inhibit the transcriptional activation of human tumor necrosis factor alpha promoter in vivo. J Biol Chem. 2004;279:5877–85.PubMedCrossRef
70.
Wang L, Li Z, Zhang X, Wang S, Zhu C, Miao J, Chen L, Cui L, Qiao H. Protective effect of shikonin in experimental ischemic stroke: attenuated TLR4, p-p38MAPK, NF-kappaB, TNF-alpha and MMP-9 expression, up-regulated claudin-5 expression, ameliorated BBB permeability. Neurochem Res. 2014;39:97–106.PubMedCrossRef
71.
Zhang FY, Hu Y, Que ZY, Wang P, Liu YH, Wang ZH, Xue YX. Shikonin inhibits the migration and invasion of human glioblastoma cells by targeting phosphorylated beta-catenin and phosphorylated PI3K/Akt: a potential mechanism for the anti-glioma efficacy of a traditional chinese herbal medicine. Int J Mol Sci. 2015;16:23823–48.PubMedPubMedCentralCrossRef
72.
Wei H, Wang S, Zhen L, Yang Q, Wu Z, Lei X, Lv J, Xiong L, Xue R. Resveratrol attenuates the blood-brain barrier dysfunction by regulation of the MMP-9/TIMP-1 balance after cerebral ischemia reperfusion in rats. J Mol Neurosci. 2015;55:872–9.PubMedCrossRef
73.
He L, Zhao C, Yan M, Zhang LY, Xia YZ. Inhibition of P-glycoprotein function by procyanidin on blood-brain barrier. Phytother Res. 2009;23:933–7.PubMedCrossRef
74.
Wu H, Liu Q, Cai T, Chen YD, Wang ZF. Induction ofmicroRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma. Mole Med Rep. 2015;12:5461–6.CrossRef
75.
Waterland RA, Jirtle RL. Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. Nutrition. 2004;20:63–8.PubMedCrossRef
76.
Yang R, Yi L, Dong Z, Ouyang Q, Zhou J, Pang Y, Wu Y, Xu L, Cui H. Tigecycline inhibits glioma growth by regulating microRNA-199b-5p-HES1-AKT pathway. Mol Cancer Ther. 2016;15:421–9.PubMedCrossRef
77.
Yan X, Liang H, Deng T, et al. The identification of novel targets of miR-16 and characterization of their biological functions in cancer cells. Mol Cancer. 2013;12:92.PubMedPubMedCentralCrossRef
78.
Tezcan G, Tunca B, Bekar A, et al. Olea europaea leaf extract improves the treatment response of GBM stem cells by modulating miRNA expression. Am J Cancer Res. 2014;4:572–90.PubMedPubMedCentral
79.
Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2010;17:215–20.PubMedCrossRef
80.
Zhu Y, Xia Y, Niu H, Chen Y. MiR-16 induced the suppression of cell apoptosis while promote proliferation in esophageal squamous cell carcinoma. Cell Physiol Biochem. 2014;33:1340–8.PubMedCrossRef
81.
Yang TQ, Lu XJ, Wu TF, Ding DD, Zhao ZH, Chen GL, Xie XS, Li B, Wei YX, Guo LC, et al. MicroRNA-16 inhibits glioma cell growth and invasion through suppression of BCL2 and the nuclear factor-kappaB1/MMP9 signaling pathway. Cancer Sci. 2014;105:265–71.PubMedPubMedCentralCrossRef
82.
Zhang Y, Chao T, Li R, Liu W, Chen Y, Yan X, et al. MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J Mol Med. 2009;87:43–51.PubMedCrossRef
83.
84.
Nan WU, Guo-cai WU, Rong HU, Mei LI, Hua FENG. Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128. Acta Pharmacol Sin. 2011;32:345–53.CrossRef
85.
Tunca B, Tezcan G, Cecener G, Egeli U, Ak S, Malyer H, Tumen G, Bilir A. Olea europaea leaf extract alters microRNA expression in human glioblastoma cells. J Cancer Res Clin Oncol. 2012;138:1831–44.PubMedCrossRef
86.
Tezcan G, Tunca B, Bekar A, et al. Olea europaea leaf extract improves the treatment response of GBM stem cells by modulating miRNA expression. Am J Cancer Res. 2014;4:572–90.PubMedPubMedCentral
87.
Tezcan G, Tunca B, Bekaretal A. Ficus carica latex prevents invasion through induction of let-7d expression in GBM cell lines. Cell Mol Neurobiol. 2015;35:175–87.PubMedCrossRef
88.
Liu J, Qu CB, Xue YX, Li Z, Wang P, Liu YH. MIR143 enhances the antitumor activity of shikonin by targeting BAG3 expression in human glioblastoma stem cells. Biochem Biophys Res Commun. 2015;468:105–12.PubMedCrossRef
89.
Yang F, Nam S, Brown CE, Zhao R, Starr R. A novel berbamine derivative inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via up-regulation of miRNA-4284 and JNK/AP-1 signaling. PLoS One. 2014;9:e94443.PubMedPubMedCentralCrossRef
90.
Li W, Yang W, Liu Y, Chen S, Chin S, Qi X, Zhao Y, Liu H, Wang J, Mei X, Huang P, Xu D. MicroRNA-378 enhances inhibitory effect of curcumin on glioblastoma. Oncotarget. 2017;8:73938–46.PubMedPubMedCentralCrossRef
91.
Agbarya A, Ruimi N, Epelbaum R, Ben-Arye E, Mahajna J. Natural products as potential cancer therapy enhancers: a preclinical update. SAGE Open Med. 2014;2:2050312114546924.PubMedPubMedCentralCrossRef
92.
93.
Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6:107–16.PubMedCrossRef
94.
Jianqing MA, Peng Y, Li X. Differential expression of Agouti mRNA and its coding protein in viscera of goat with different coat color. Indian J Anim Res. 2016;50:690–4.
95.
Vanden BW. Epigenetic impact of dietary polyphenols in cancer chemoprevention: lifelong remodeling of our epigenomes. Pharmacol Res. 2012;65:565–76.CrossRef
96.
Hardy TM, Tollefsbol TO. Epigenetic diet: impact on the epigenome and cancer. Epigenomics. 2011;3:503–18.PubMedCrossRef
97.
Wu B, Yao X, Nie X, Xu R. Epigenetic reactivation of RANK in glioblastoma cells by curcumin: involvement of STAT3 inhibition. DNA Cell Biol. 2013;32:292–7.PubMedPubMedCentralCrossRef
98.
Skała E, Toma M, Kowalczyk T, Sliwinski T, Sitarek P. Rhaponticum carthamoides transformed root extract inhibits human glioma cells viability, induces double strand DNA damage, H2A.X phosphorylation, and PARP1 cleavage. Cytotechnology. 2018;70:1585–94.PubMedPubMedCentralCrossRef
99.
100.
Kelly WK, O’Connor OA, Marks PA. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Invest Drugs. 2002;11:1695–713.CrossRef
101.
Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol. 2002;196:1–7.PubMedCrossRef
102.
Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther. 2009;8:1409–20.PubMedCrossRef
103.
Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31–9.PubMedPubMedCentralCrossRef
104.
Campas-Moya C. Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today. 2009;45:787–95.CrossRef
105.
Vargas JE, Filippi-Chiela EC, Suhre T, Kipper FC, Bonatto D, Lenz G. Inhibition of HDAC increases the senescence induced by natural polyphenols in glioma cells. Biochem Cell Biol. 2014;92:297–304.PubMedCrossRef
106.
Jiao Y, Killela PJ, Reitman ZJ, Rasheed A, Heaphy CM, de Wilde RF, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3:710–22.CrossRef
107.
Ebrahimi A, Skardelly M, Bonzheim I, Ott I, Mühleisen H, Eckert F, Tabatabai G, Schittenhelm J. ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathol Commun. 2016;4:60.PubMedPubMedCentralCrossRef
108.
Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;2012:264–78.CrossRef
109.
110.
Dong Z, Abbas MN, Kausar S, Yang J, Li L, Tan L, Cui H. Biological functions and molecular mechanisms of antibiotic tigecycline in the treatment of cancers. Int J Mol Sci. 2019;20:3577.PubMedCentralCrossRef
111.
Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–44.PubMedPubMedCentralCrossRef
112.
Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19:17–30.PubMedPubMedCentralCrossRef
113.
Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011;12:463–9.PubMedPubMedCentralCrossRef
114.
Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722–31.PubMedPubMedCentralCrossRef
115.
Sharma H. Development of novel therapeutics targeting isocitrate dehydrogenase mutations in cancer. Curr Top Med Chem. 2018;18:505–24.PubMedCrossRef
Metadata
Title
Therapeutic potential of natural products in glioblastoma treatment: targeting key glioblastoma signaling pathways and epigenetic alterations
Authors
M. N. Abbas
S. Kausar
H. Cui
Publication date
01-07-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 7/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02227-3

Other articles of this Issue 7/2020

Clinical and Translational Oncology 7/2020 Go to the issue

Research Article

Novel exosomal miR-46146 transfer oxaliplatin chemoresistance in colorectal cancer

Research Article

Splenic volume as a biomarker of hepatic damage after chemotherapy in patients with resected colorectal liver metastases (CRLM)

Research Article

PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer

Research Article

Prognostic value of peptidyl-prolyl cis–trans isomerase 1 (PIN1) in human malignant tumors

Review Article

Li–Fraumeni syndrome heterogeneity

Research Article

Baicalein, an enteric microbial metabolite, suppresses gut inflammation and cancer progression in ApcMin/+ mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits